Stereotactic Body Radiotherapy for Pulmonary Oligometastases from Esophageal Cancer: Results and Prognostic Factors

TAKAYA YAMAMOTO; YUZURU NIIBE; YASUO MATSUMOTO; YASUHIRO DEKURA; RYOONG-JIN OH; HIDEOMI YAMASHITA; HISAO KAKUHARA; MASAHIKO AOKI; KEIICHI JINGU

doi:10.21873/anticanres.14164

Abstract

Background/Aim: The aim of this multi-center retrospective study was to investigate the results of stereotactic body radiotherapy (SBRT) for pulmonary oligometastases from esophageal cancer. Patients and Methods: Oligometastases from the esophagus were identified from a dataset of a Japanese survey. The Kaplan–Meier method and Cox regression were applied to perform analyses. Results: A total of 114 patients with 132 pulmonary oligometastases were collected. The 3-year local control rate, freedom from further metastasis (FFFM) rate and overall survival (OS) rate were 70.2%, 25.3% and 37.5%, respectively. Performance status (PS) (PS 1 vs. PS 0, p<0.01), disease-free interval (p=0.03) and history of local therapy for metastasis (p=0.01) had significant relationships with FFFM and only PS was an independent prognostic factor for OS (PS 1 vs. PS 0, p=0.02; PS 2-3 vs. PS 0, p=0.04). Conclusion: SBRT for pulmonary oligometastases from esophageal cancer provided good local control and survival.

Footnotes

Authors' Contributions
TY drafted the protocol, collected patients, performed data analysis and interpretation and wrote the manuscript. NY conceived and designed the study, drafted the protocol and collected patients. YM, YD, R-JO, HY, HK and MA collected patients. KJ advised data analysis and interpretation and revised the manuscript. All Authors read and approved the manuscript.
Conflicts of Interest
The Authors declare no conflicts of interest associated with this manuscript.
Funding
This study was supported by Grant-in-aid for research on radiation oncology of JASTRO 2015-2016.

Received February 23, 2020.
Revision received March 1, 2020.
Accepted March 4, 2020.

View Full Text

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.